NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

Talimogene Laherparepvec:醫藥品分析、市場預測 (∼2030年)

Talimogene Laherparepvec- Drug Insight and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 973316
出版日期 按訂單生產 內容資訊 英文 50 Pages
商品交期: 10個工作天內
價格
Talimogene Laherparepvec:醫藥品分析、市場預測 (∼2030年) Talimogene Laherparepvec- Drug Insight and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 50 Pages
簡介

本報告提供全球主要7個國家Talimogene Laherparepvec的市場調查,產品概要,作用機制,用法、用量,相關法律,已上市藥概要、趨勢,開發平台趨勢,主要7個國家主要趨勢,市場規模的變化、預測,主要經營者等資料彙整。

第1章 產品概要

  • 表示
  • 作用機制
  • 投藥、管理
  • 合成途徑
  • 藥理分析
  • 副作用
  • 產品概要
  • 開發上的里程碑
  • 銷售趨勢
    • 美國
    • 歐洲
    • 日本
  • 專利詳細內容

第2章 SWOT分析

  • 分析師的見解

第3章 法規上的里程碑

  • 核准
  • R&D
  • 臨床試驗資訊
  • 安全性、有效性
  • 產品開發活動

第4章 市場評估

  • 市場分析主要7個國家
  • 美國
  • 歐洲
  • 日本
  • 主要調查結果

第5章 主要企業

第6章 新治療方法

第7章 附錄

目錄
Product Code: DIDM0068

"Talimogene Laherparepvec- Drug Insight and Market Forecast - 2030" report by DelveInsight outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Talimogene Laherparepvec in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017-2030 is provided in this report along with a detailed description of the product. The product details covers mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.

Drug Summary:

Talimogene Laherparepvec (Imlygic) is a genetically modified herpes simplex virus type 1 injected directly into tumors where it replicates inside tumors and produces GM-CSF, an immunostimulatory protein. IMLYGIC then causes the tumor to rupture and die in a process called lysis. The rupture of the tumor causes the release of tumor-derived antigens, which together with virally-derived GM-CSF may promote an anti-tumor immune response. However, the exact mechanism of action is unknown and being further investigated. IMLYGIC is the first oncolytic viral therapy approved by the FDA based on therapeutic benefit demonstrated in a pivotal study.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and adverse reactions.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug marketed details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around Talimogene Laherparepvec.
  • The report contains historical and forecasted sales for Talimogene Laherparepvec till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.
  • The report also features the SWOT analysis with analyst insights and key findings of Talimogene Laherparepvec.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Talimogene Laherparepvec Analytical Perspective by DelveInsight

  • In-depth Talimogene Laherparepvec Market Assessment

This report provides a detailed market assessment of Talimogene Laherparepvec in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2017 to 2030.

  • Talimogene Laherparepvec Clinical Assessment

The report provides the clinical trials information of Talimogene Laherparepvec covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Talimogene Laherparepvec is set to change due to the extensive research in the treatment of the indicated condition and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Talimogene Laherparepvec dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other approved products for the disease are giving market competition to Talimogene Laherparepvec and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current market scenario of Talimogene Laherparepvec.
  • Our in-depth analysis of the sales data of Talimogene Laherparepvec from 2017 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Talimogene Laherparepvec in the market.

Key Questions:

  • What is the prescribed dosage and strengths of Talimogene Laherparepvec are available in the market?
  • What are the common adverse reactions or side effects of Talimogene Laherparepvec?
  • What is the product type, route of administration and mechanism of action of Talimogene Laherparepvec?
  • What are the chemical specifications of Talimogene Laherparepvec?
  • How are the clinical trials diversified on the basis of the trial status?
  • What is the history of Talimogene Laherparepvec, and what is its future?
  • What are the marketed details of Talimogene Laherparepvec in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • How many patents have been granted to Talimogene Laherparepvec and when these patents will get expire?
  • What are the pros (benefits) and cons (disadvantages) of Talimogene Laherparepvec?
  • In which countries Talimogene Laherparepvec got approval and when it gets launched?
  • What are the clinical trials are currently ongoing for Talimogene Laherparepvec?
  • How the safety and efficacy results determined the approval of Talimogene Laherparepvec?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Talimogene Laherparepvec development?
  • What are the key designations that have been granted to Talimogene Laherparepvec?
  • What is the historical and forecasted market scenario of Talimogene Laherparepvec?
  • How is the market trend of Talimogene Laherparepvec is different in the Seven Major Markets (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)?
  • What are the other approved products available and how these are giving competition to Talimogene Laherparepvec?
  • Which are the late-stage emerging therapies under development for the treatment of the indicated condition?

Table of Contents

1. Product Overview

  • 1.1. Indication
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
    • 1.4.1 Dosage Forms and Strengths
  • 1.4. Route of Synthesis
  • 1.5. Pharmacology
    • 1.4.2 Pharmacodynamics
    • 1.4.3 Pharmacokinetics
  • 1.6. Adverse Reactions
  • 1.7. Product Snapshot
  • 1.8. Development Milestones of Talimogene Laherparepvec
  • 1.9. Marketed Details
    • 1.4.4 United States
    • 1.4.5 Europe
    • 1.4.6 Japan
  • 1.10. Patent Details

2. SWOT Analysis

  • 2.1. Analyst Views

3. Regulatory Milestones

  • 3.1. Approvals
  • 3.2. Research and Development
  • 3.3. Clinical Trials Information
  • 3.4. Safety and Efficacy
  • 3.5. Product Developmental Activities

4. Market Assessment

  • 4.1. 7MM Market Analysis
  • 4.2. United States
  • 4.3. Europe
  • 4.4. Japan
  • 4.5. Key Findings

5. Market Competitors

6. Emerging Therapies

7. Appendix

  • 7.1. Report Purchase Options

List of Tables

  • Table 1 Talimogene Laherparepvec, Description
  • Table 2 Talimogene Laherparepvec, Trial Diversification
  • Table 3 Talimogene Laherparepvec, Marketed Details United States
  • Table 4 Talimogene Laherparepvec, Marketed Details Europe
  • Table 5 Talimogene Laherparepvec, Marketed Details Japan
  • Table 6 Patent Details: Talimogene Laherparepvec
  • Table 7 Talimogene Laherparepvec, Clinical Trial Description, 2020
  • Table 8 Safety and Efficacy Results for Talimogene Laherparepvec
  • Table 9 Talimogene Laherparepvec, 7MM Market Size from 2017 to 2030 (in Million USD)
  • Table 10 Talimogene Laherparepvec, US Market Size from 2017 to 2030 (in Million USD)
  • Table 11 Talimogene Laherparepvec, EU Market Size from 2017 to 2030 (in Million USD)
  • Table 12 Talimogene Laherparepvec, EU5 Market Size from 2017 to 2030 (in Millions USD)
  • Table 13 Talimogene Laherparepvec, Japan Market Size from 2017 to 2030 (in Million USD)
  • Table 14 Market Competitors
  • Table 15 Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of Talimogene Laherparepvec
  • Figure 2 Patent Details, Talimogene Laherparepvec
  • Figure 3 Talimogene Laherparepvec, 7MM Market Size from 2017 to 2030 (in Million USD)
  • Figure 4 Talimogene Laherparepvec, US Market Size from 2017 to 2030 (in Millions USD)
  • Figure 5 Talimogene Laherparepvec, EU Market Size from 2017 to 2030 (in Millions USD)
  • Figure 6 Talimogene Laherparepvec, EU5 Market Size from 2017 to 2030 (in Millions USD)
  • Figure 7 Talimogene Laherparepvec, Japan Market Size from 2017 to 2030 (in Millions USD)